RxDoctor Payments Data

Jennifer Tuccio, NP

Family · Clinton, MSNPI 1871872820

Payments from drug & device makers

$2,634in general payments, 2019–2025

Across 145 payments — averaging $18.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$550
  • Pfizer$376
  • AstraZeneca$255
  • Lilly USA, LLC$200
  • Novo Nordisk$162
  • GSK$154
  • plus $937 from 21 others

What the payments were for

  • Food & beverage$2,634100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,634 in reported general payments places this provider in the 85th percentile of 3,007 family providers in Mississippi.

See all family providers in Mississippi

Medicare billing

Part B allowed, 2024
$74,876
Medicare patients
332
Services billed
1,828

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide21$43,243
EliquisApixaban24$20,188
JardianceEmpagliflozin13$19,112
FarxigaDapagliflozin Propanediol13$14,150
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$8,985
Tresiba Flextouch U-100Insulin Degludec15$8,857
Potassium Chloride87$1,422
Albuterol Sulfate HfaAlbuterol Sulfate48$1,343
Doxycycline Hyclate106$1,155
Cefdinir48$873
Fluticasone Propionate59$796
Atorvastatin Calcium100$720
Nifedipine ErNifedipine29$693
Pantoprazole Sodium58$624
Rosuvastatin Calcium58$544

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$162$43,24321 claims
PfizerEliquis$376$20,18824 claims
Boehringer IngelheimJardiance$40$19,11213 claims
AstraZenecaFarxiga$255$14,15013 claims
GSKTrelegy Ellipta$154$8,98514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,007 family providers in Mississippi.

Other family in Clinton

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →